The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature

Cancers

Volumn 2, Issue 2, 2010, Pages 885-912

  Grogan, Raymon H ^a   Mitmaker, Elliot J ^a   Clark, Orlo H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biological marker; Biomarker; Epigenetics; Genomics; Molecular marker; Molecular pathways; Proteomics; Serum based biomarkers; Thyroid cancer; Tumor marker

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CELL DNA; MESSENGER RNA; MICRORNA; THYROGLOBULIN; TUMOR MARKER;

ASPIRATION BIOPSY; BRAF GENE; CANCER CONTROL; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CARCINOGENESIS; DIAGNOSTIC ACCURACY; DNA METHYLATION; EPIGENETICS; FAMILIAL CANCER; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENETIC SCREENING; GENOMICS; HIGH THROUGHPUT SCREENING; HORMONE DETERMINATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MASS SCREENING; MICROSATELLITE INSTABILITY; NTRK1 GENE; ONCOGENE RET; PAX8 GENE; PERSONALIZED BIOSIGNATURE; POINT MUTATION; PPAR GAMMA GENE; PREDICTION; PROTEOMICS; PROVOCATION TEST; PTC GENE; QUANTITATIVE DIAGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID ADENOMA; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROIDECTOMY; TUMOR SUPPRESSOR GENE;

EID: 79952262530     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2020885     Document Type: Review

References (129)

1. Milhaud, G.; Calmette, C.; Taboulet, J.; Julienne, A.; Moukhtar, M.S. Letter: Hypersecretion of calcitonin in neoplastic conditions. Lancet 1974, 1, 462-463.
2. Melvin, K.E.; Miller, H.H.; Tashjian, A.H. Early diagnosis of medullary carcinoma of the thyroid gland by means of calcitonin assay. N. Engl. J. Med. 1971, 285, 1115-1120.
3. Srinivas, P.R.; Kramer, B.S.; Srivastava, S. Trends in biomarker research for cancer detection. Lancet Oncol. 2001, 2, 698-704.
4. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59, 225-249.
5. Davies, L.; Welch, H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295, 2164-2167.
6. National Cancer Institute. Age-Adjusted SEER Incidence Rates By Cancer Site Ages < 50, All Races, Female 2000 - 2006 (SEER 17) Surveillance, Epidemiology, and End Results (SEER) Program. Available on line at: http://www.seer.cancer.gov/ (accessed on 24 February 2010).
7. Shibru, D.; Chung, K.W.; Kebebew, E. Recent developments in the clinical application of thyroid cancer biomarkers. Curr. Opin. Oncol. 2008, 20, 13-18.
8. Van Herle, A.J.; Uller, R.P.; Matthews, N.I.; Brown, J. Radioimmunoassay for measurement of thyroglobulin in human serum. J. Clin. Invest. 1973, 52, 1320-1327.
9. Tashijan, A.H.; Howland, B.G.; Melvin, K.E.; Hill, C.S. Immunoassay of human calcitonin. N. Engl. J. Med. 1970, 283, 890-895.
10. Jensen, M.B.; Chacon, M.R.; Sattin, J.A.; Aleu, A.; Lyden, P.D. The promise and potential pitfalls of serum biomarkers for ischemic stroke and transient ischemic attack. Neurologist 2008, 14, 243-246.
11. R.B. Immunologic tests in diagnosis of cancer. Am. J. Clin. Pathol. 1977, 68, 688-698.
12. Holyoke, E.D.; Block, G.E.; Jensen, E.; Sizemore, G.W.; Heath, H.; Chu, T.M.; Murphy, G.P.; Mittelman, A.; Ruddon, R.W.; Arnott, M.S. Biologic markers in cancer diagnosis and treatment. Curr. Probl. Cancer 1981, 6, 1-68.
13. Bieglmayer, C.; Vierhapper, H.; Dudczak, R.; Niederle, B. Measurement of calcitonin by immunoassay analyzers. Clin. Chem. Lab. Med. 2007, 45, 662-666.
14. Guilloteau, D.; Perdrisot, R.; Calmettes, C.; Baulieu, J.L.; Lecomte, P.; Kaphan, G.; Milhaud, G.; Besnard, J.C.; Jallet, P.; Bigorgne, J.C. Diagnosis of medullary carcinoma of the thyroid (MCT) by calcitonin assay using monoclonal antibodies: criteria for the pentagastrin stimulation test in hereditary MCT. J. Clin. Endocrinol. Metab. 1990, 71, 1064-1067.
15. d'Herbomez, M.; Caron, P.; Bauters, C.; Cao, C.D.; Schlienger, J.L.; Sapin, R.; Baldet, L.; Carnaille, B.; Wémeau, J.L.; French Group GTE (Groupe des Tumeurs Endocrines) Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur. J. Endocrinol. 2007, 157, 749-755.
16. Toledo, S.P.; Lourenço, D.M.; Santos, M.A.; Tavares, M.R.; Toledo, R.A.; Correia-Deur, J.E. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo) 2009, 64, 699-706.
17. van Veelen, W.; de Groot, J.W.; Acton, D.S.; Hofstra, R.M.; Höppener, J.W.; Links, T.P.; Lips, C.J. Medullary thyroid carcinoma and biomarkers: past, present and future. J. Intern. Med. 2009, 266, 126-140.
18. Cohen, R.; Campos, J.M.; Salaün, C.; Heshmati, H.M.; Kraimps, J.L.; Proye, C.; Sarfati, E.; Henry, J.F.; Niccoli-Sire, P.; Modigliani, E. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J. Clin. Endocrinol. Metab. 2000, 85, 919-922.
19. Laure Giraudet, A.; Al Ghulzan, A.; Aupérin, A.; Leboulleux, S.; Chehboun, A.; Troalen, F.; Dromain, C.; Lumbroso, J.; Baudin, E.; Schlumberger, M. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur. J. Endocrinol. 2008, 158, 239-246.
20. Lippman, S.M.; Mendelsohn, G.; Trump, D.L.; Wells, S.A.; Baylin, S.B. The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase. J. Clin. Endocrinol. Metab. 1982, 54, 233-240.
21. Wells, S.A.; Chi, D.D.; Toshima, K.; Dehner, L.P.; Coffin, C.M.; Dowton, S.B.; Ivanovich, J.L.; DeBenedetti, M.K.; Dilley, W.G.; Moley, J.F. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann. Surg. 1994, 220, 237-250.
22. Eng, C.; Smith, D.P.; Mulligan, L.M.; Healey, C.S.; Zvelebil, M.J.; Stonehouse, T.J.; Ponder, M.A.; Jackson, C.E.; Waterfield, M.D.; Ponder, B.A. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995, 10, 509-513.
23. Wong, J.; Lu, Z.; Doery, J.; Fuller, P. Lessons from a review of thyroglobulin assays in the management of thyroid cancer. Intern. Med. J. 2008, 38, 441-444.
24. Whitley, R.J.; Ain, K.B. Thyroglobulin: a specific serum marker for the management of thyroid carcinoma. Clin. Lab. Med. 2004, 24, 29-47.
25. Gupta, M.; Chia, S.Y. Circulating thyroid cancer markers. Curr. Opin. Endocrinol. Diabetes Obes. 2007, 14, 383-388.
26. Spencer, C.A.; Bergoglio, L.M.; Kazarosyan, M.; Fatemi, S.; LoPresti, J.S. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 2005, 90, 5566-5575.
27. Haugen, B.R.; Pacini, F.; Reiners, C.; Schlumberger, M.; Ladenson, P.W.; Sherman, S.I.; Cooper, D.S.; Graham, K.E.; Braverman, L.E.; Skarulis, M.C.; et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J. Clin. Endocrinol. Metab. 1999, 84, 3877-3885.
28. Refetoff, S.; Lever, E.G. The value of serum thyroglobulin measurement in clinical practice. JAMA 1983, 250, 2352-2357.
29. Ishikawa, T.; Miwa, M.; Uchida, K. Quantitation of thyroid peroxidase mRNA in peripheral blood for early detection of thyroid papillary carcinoma. Thyroid 2006, 16, 435-442.
30. Mercken, L.; Simons, M.J.; Brocas, H.; Vassart, G. Alternative splicing may be responsible for heterogeneity of thyroglobulin structure. Biochimie 1989, 71, 223-226.
31. Chinnappa, P.; Taguba, L.; Arciaga, R.; Faiman, C.; Siperstein, A.; Mehta, A.E.; Reddy, S.K.; Nasr, C.; Gupta, M.K. Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer. J. Clin. Endocrinol. Metab. 2004, 89, 3705-3709.
32. Mulligan, L.M.; Kwok, J.B.; Healey, C.S.; Elsdon, M.J.; Eng, C.; Gardner, E.; Love, D.R.; Mole, S.E.; Moore, J.K.; Papi, L. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363, 458-460.
33. Knyazev, P.G.; Fedorov, S.N.; Serova, O.M.; Pluzhnikova, G.F.; Novikov, L.B.; Kalinovsky, V.P.; Seitz, J.F. Molecular-genetic analysis of myc and c-Ha-ras proto-oncogene alterations in human carcinoma. Haematol. Blood Transfus. 1987, 31, 469-473.
34. Grieco, M.; Santoro, M.; Berlingieri, M.T.; Melillo, R.M.; Donghi, R.; Bongarzone, I.; Pierotti, M.A.; Della Porta, G.; Fusco, A.; Vecchio, G. PTC is a novel rearranged form of the ret protooncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60, 557-563.
35. Ito, T.; Seyama, T.; Mizuno, T.; Tsuyama, N.; Hayashi, T.; Hayashi, Y.; Dohi, K.; Nakamura, N.; Akiyama, M. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 1992, 52, 1369-1371.
36. Greco, A.; Pierotti, M.A.; Bongarzone, I.; Pagliardini, S.; Lanzi, C.; Della Porta, G. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene 1992, 7, 237-242.
37. Kroll, T.G.; Sarraf, P.; Pecciarini, L.; Chen, C.J.; Mueller, E.; Spiegelman, B.M.; Fletcher, J.A. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected] Science 2000, 289, 1357-1360.
38. Kimura, E.T.; Nikiforova, M.N.; Zhu, Z.; Knauf, J.A.; Nikiforov, Y.E.; Fagin, J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003, 63, 1454-1457.
39. M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 2005, 12, 245-262.
40. Nikiforov, Y.E. RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 2002, 13, 3-16.
41. Ezzat, S.; Zheng, L.; Kolenda, J.; Safarian, A.; Freeman, J.L.; Asa, S.L. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 1996, 6, 409-416.
42. Placzkowski, K.A.; Reddi, H.V.; Grebe, S.K.; Eberhardt, N.L.; McIver, B. The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer. PPAR Res. 2008, 2008, 672829.
43. Sobrinho-Simões, M.; Máximo, V.; Rocha, A.S.; Trovisco, V.; Castro, P.; Preto, A.; Lima, J.; Soares, P. Intragenic mutations in thyroid cancer. Endocrinol. Metab. Clin. North Am. 2008, 37, 333-362.
44. Greco, A.; Miranda, C.; Pierotti, M.A. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol. Cell Endocrinol. 2009, 321, 44-49.
45. Kebebew, E.; Weng, J.; Bauer, J.; Ranvier, G.; Clark, O.H.; Duh, Q.Y.; Shibru, D.; Bastian, B.; Griffin, A. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg. 2007, 246, 466-471.
46. Soares, P.; Trovisco, V.; Rocha, A.S.; Lima, J.; Castro, P.; Preto, A.; Máximo, V.; Botelho, T.; Seruca, R.; Sobrinho-Simões, M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22, 4578-4580.
47. Trovisco, V.; Vieira de Castro, I.; Soares, P.; Máximo, V.; Silva, P.; Magalhães, J.; Abrosimov, A.; Guiu, X.M.; Sobrinho-Simões, M. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J. Pathol. 2004, 202, 247-251.
48. Xing, M.; Westra, W.H.; Tufano, R.P.; Cohen, Y.; Rosenbaum, E.; Rhoden, K.J.; Carson, K.A.; Vasko, V.; Larin, A.; Tallini, G.; et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2005, 90, 6373-6379.
49. Kim, T.Y.; Kim, W.B.; Song, J.Y.; Rhee, Y.S.; Gong, G.; Cho, Y.M.; Kim, S.Y.; Kim, S.C.; Hong, S.J.; Shong, Y.K. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin. Endocrinol. (Oxf.) 2005, 63, 588-593.
50. Lee, J.H.; Lee, E.S.; Kim, Y.S. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007, 110, 38-46.
51. Takahashi, M.; Ritz, J.; Cooper, G.M. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985, 42, 581-588.
52. Simpson, N.E.; Kidd, K.K.; Goodfellow, P.J.; McDermid, H.; Myers, S.; Kidd, J.R.; Jackson, C.E.; Duncan, A.M.; Farrer, L.A.; Brasch, K. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 1987, 328, 528-530.
53. Takahashi, M.; Buma, Y.; Iwamoto, T.; Inaguma, Y.; Ikeda, H.; Hiai, H. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988, 3, 571-578.
54. Ishizaka, Y.; Itoh, F.; Tahira, T.; Ikeda, I.; Sugimura, T.; Tucker, J.; Fertitta, A.; Carrano, A.V.; Nagao, M. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene 1989, 4, 1519-1521.
55. Yamamoto, M.; Miki, T.; Tanaka, N.; Miya, A.; Shin, E.; Karakawa, K.; Kobayashi, T.; Tahira, T.; Ishizaka, Y.; Itoh, F. Tight linkage of the ret proto-oncogene with the multiple endocrine neoplasia type 2A locus. Jpn. J. Clin. Oncol. 1991, 21, 149-152.
56. Mole, S.E.; Mulligan, L.M.; Healey, C.S.; Ponder, B.A.; Tunnacliffe, A. Localisation of the gene for multiple endocrine neoplasia type 2A to a 480 kb region in chromosome band 10q11.2. Hum. Mol. Genet. 1993, 2, 247-252.
57. Donis-Keller, H.; Dou, S.; Chi, D.; Carlson, K.M.; Toshima, K.; Lairmore, T.C.; Howe, J.R.; Moley, J.F.; Goodfellow, P.; Wells, S.A. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 1993, 2, 851-856.
58. Skinner, M.A.; Moley, J.A.; Dilley, W.G.; Owzar, K.; Debenedetti, M.K.; Wells, S.A. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N. Engl. J. Med. 2005, 353, 1105-1113.
59. Machens, A.; Niccoli-Sire, P.; Hoegel, J.; Frank-Raue, K.; van Vroonhoven, T.J.; Roeher, H.D.; Wahl, R.A.; Lamesch, P.; Raue, F.; Conte-Devolx, B.; et al. Early malignant progression of hereditary medullary thyroid cancer. N. Engl. J. Med. 2003, 349, 1517-1525.
60. American Thyroid Association Guidelines Task Force; Kloos, R.T.; Eng, C.; Evans, D.B.; Francis, G.L.; Gagel, R.F.; Gharib, H.; Moley, J.F.; Pacini, F.; Ringel, M.D.; et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19, 565-612.
61. Garcia-Rostan, G.; Zhao, H.; Camp, R.L.; Pollan, M.; Herrero, A.; Pardo, J.; Wu, R.; Carcangiu, M.L.; Costa, J.; Tallini, G. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J. Clin. Oncol. 2003, 21, 3226-3235.
62. Nikiforova, M.N.; Lynch, R.A.; Biddinger, P.W.; Alexander, E.K.; Dorn, G.W.; Tallini, G.; Kroll, T.G.; Nikiforov, Y.E. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 2003, 88, 2318-2326.
63. Morita, N.; Ikeda, Y.; Takami, H. Clinical significance of p53 protein expression in papillary thyroid carcinoma. World J. Surg. 2008, 32, 2617-2622.
64. Jossart, G.H.; Epstein, H.D.; Shaver, J.K.; Weier, H.U.; Greulich, K.M.; Tezelman, S.; Grossman, R.F.; Siperstein, A.E.; Duh, Q.Y.; Clark, O.H. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines. J. Clin. Endocrinol. Metab. 1996, 81, 3498-3504.
65. Park, K.Y.; Koh, J.M.; Kim, Y.I.; Park, H.J.; Gong, G.; Hong, S.J.; Ahn, I.M. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin. Endocrinol. (Oxf) 1998, 49, 317-323.
66. Pollina, L.; Pacini, F.; Fontanini, G.; Vignati, S.; Bevilacqua, G.; Basolo, F. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br. J. Cancer 1996, 73, 139-143.
67. Musholt, T.J.; Musholt, P.B.; Khaladj, N.; Schulz, D.; Scheumann, G.F.W.; Klempnauer, J. Prognostic significance of RET and NTRK 1 rearrangements in sporadic papillary thyoid carcinoma. Br. J. Surg. 2000, 87, 1256-1278.
68. Nikiforov, Y.E.; Steward, D.L.; Robinson-Smith, T.M.; Haugen, B.R.; Klopper, J.P.; Zhu, Z.; Fagin, J.A.; Falciglia, M.; Weber, K.; Nikiforova, M.N. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J. Clin. Endocrinol. Metab. 2009, 94, 2092-2098.
69. Ionov, Y.; Peinado, M.A.; Malkhosyan, S.; Shibata, D.; Perucho, M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993, 363, 558-561.
70. Soares, P.; dos Santos, N.R.; Seruca, R.; Lothe, R.A.; Sobrinho-Simões, M. Benign and malignant thyroid lesions show instability at microsatellite loci. Eur. J. Cancer 1997, 33, 293-296.
71. Onda, M.; Nakamura, I.; Suzuki, S.; Takenoshita, S.; Brogren, C.H.; Stampanoni, S.; Li, D.; Rampino, N. Microsatellite instability in thyroid cancer: hot spots, clinicopathological implications, and prognostic significance. Clin. Cancer Res. 2001, 7, 3444-3449.
72. Mitmaker, E.; Alvarado, C.; Bégin, L.R.; Trifiro, M. Microsatellite instability in benign and malignant thyroid neoplasms. J. Surg. Res. 2008, 150, 40-48.
73. Vermiglio, F.; Schlumberger, M.; Lazar, V.; Lefrere, I.; Bressac, B. Absence of microsatellite instability in thyroid carcinomas Eur. J. Cancer 1995, 31, 128-128.
74. Xing, M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007, 148, 948-953.
75. Alvarez-Nuñez, F.; Bussaglia, E.; Mauricio, D.; Ybarra, J.; Vilar, M.; Lerma, E.; de Leiva, A.; Matias-Guiu, X.; Thyroid Neoplasia Study Group PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 2006, 16, 17-23.
76. Hoque, M.O.; Rosenbaum, E.; Westra, W.H.; Xing, M.; Ladenson, P.; Zeiger, M.A.; Sidransky, D.; Umbricht, C.B. Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J. Clin. Endocrinol. Metab. 2005, 90, 4011-4018.
77. Hu, S.; Liu, D.; Tufano, R.P.; Carson, K.A.; Rosenbaum, E.; Cohen, Y.; Holt, E.H.; Kiseljak-Vassiliades, K.; Rhoden, K.J.; Tolaney, S.; et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int. J. Cancer 2006, 119, 2322-2329.
78. Kondo, Y.; Issa, J.P.J. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004, 23, 29-39.
79. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843-854.
80. Drakaki, A.; Iliopoulos, D. MicroRNA Gene Networks in Oncogenesis. Curr. Genomics 2009, 10, 35-41.
81. Medina, P.P.; Slack, F.J. microRNAs and cancer: an overview. Cell Cycle 2008, 7, 2485-2492.
82. He, H.; Jazdzewski, K.; Li, W.; Liyanarachchi, S.; Nagy, R.; Volinia, S.; Calin, G.A.; Liu, C.G.; Franssila, K.; Suster, S.; et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl. Acad. Sci. U S A 2005, 102, 19075-19080.
83. Nikiforova, M.N.; Chiosea, S.I.; Nikiforov, Y.E. MicroRNA expression profiles in thyroid tumors. Endocr. Pathol. 2009, 20, 85-91.
84. Chen, Y.T.; Kitabayashi, N.; Zhou, X.K.; Fahey, T.J.; Scognamiglio, T. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod. Pathol. 2008, 21, 1139-1146.
85. McKusick, V.A.; Ruddle, F.H. A new discipline, a new name, a new journal. Genomics 1987, 1, 1-2.
86. S. Technological platforms for microarray gene expression profiling. Adv. Exp. Med. Biol. 2007, 593, 12-18.
87. Lee, N.H.; Saeed, A.I. Microarrays: an overview. Methods Mol. Biol. 2007, 353, 265-300.
88. Hoheisel, J.D. Microarray technology: beyond transcript profiling and genotype analysis. Nat. Rev. Genet. 2006, 7, 200-210.
89. Huang, Y.; Prasad, M.; Lemon, W.J.; Hampel, H.; Wright, F.A.; Kornacker, K.; LiVolsi, V.; Frankel, W.; Kloos, R.T.; Eng, C.; et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc. Natl. Acad. Sci. USA 2001, 98, 15044-15049.
90. Giordano, T.J.; Kuick, R.; Thomas, D.G.; Misek, D.E.; Vinco, M.; Sanders, D.; Zhu, Z.; Ciampi, R.; Roh, M.; Shedden, K.; et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005, 24, 6646-6656.
91. Lui, W.O.; Foukakis, T.; Lidén, J.; Thoppe, S.R.; Dwight, T.; Höög, A.; Zedenius, J.; Wallin, G.; Reimers, M.; Larsson, C. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR(gamma) fusion oncogene. Oncogene 2005, 24, 1467-1476.
92. Vasko, V.; Espinosa, A.V.; Scouten, W.; He, H.; Auer, H.; Liyanarachchi, S.; Larin, A.; Savchenko, V.; Francis, G.L.; de la Chapelle, A.; et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc. Natl. Acad. Sci. USA 2007, 104, 2803-2808.
93. Detours, V.; Delys, L.; Libert, F.; Weiss Solís, D.; Bogdanova, T.; Dumont, J.E.; Franc, B.; Thomas, G.; Maenhaut, C. Genome-wide gene expression profiling suggests distinct radiation susceptibilities in sporadic and post-Chernobyl papillary thyroid cancers. Br. J. Cancer 2007, 97, 818-825.
94. Griffith, O.L.; Melck, A.; Jones, S.J.; Wiseman, S.M. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J. Clin. Oncol. 2006, 24, 5043-5051.
95. Wilkins, M.R.; Pasquali, C.; Appel, R.D.; Ou, K.; Golaz, O.; Sanchez, J.C.; Yan, J.X.; Gooley, A.A.; Hughes, G.; Humphery-Smith, I.; et al. From Proteins to Proteomes: Large Scale Protein Identification by Two-Dimensional Electrophoresis and Arnino Acid Analysis Nat. Biotech. 1996, 14, 61-65.
96. Fischer, S.; Asa, S.L. Application of immunohistochemistry to thyroid neoplasms. Arch. Pathol. Lab. Med. 2008, 132, 359-372.
97. Volante, M.; Bozzalla-Cassione, F.; Orlandi, F.; Papotti, M. Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Arch. 2004, 444, 309-312.
98. Torregrossa, L.; Faviana, P.; Camacci, T.; Materazzi, G.; Berti, P.; Minuto, M.; Elisei, R.; Vitti, P.; Miccoli, P.; Basolo, F. Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity. Hum. Pathol. 2007, 38, 1482-1488.
99. Türköz, H.K.; Oksüz, H.; Yurdakul, Z.; Ozcan, D. Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr. Pathol. 2008, 19, 92-96.
100. Saussez, S.; Glinoer, D.; Chantrain, G.; Pattou, F.; Carnaille, B.; André, S.; Gabius, H.J.; Laurent, G. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 2008, 18, 705-712.
101. Rossi, E.D.; Raffaelli, M.; Mule', A.; Miraglia, A.; Lombardi, C.P.; Vecchio, F.M.; Fadda, G. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 2006, 48, 795-800.
102. Saggiorato, E.; De Pompa, R.; Volante, M.; Cappia, S.; Arecco, F.; Dei Tos, A.P.; Orlandi, F.; Papotti, M. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr. Relat. Cancer 2005, 12, 305-317.
103. Scognamiglio, T.; Hyjek, E.; Kao, J.; Chen, Y.T. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am. J. Clin. Pathol. 2006, 126, 700-708.
104. Wiseman, S.M.; Melck, A.; Masoudi, H.; Ghaidi, F.; Goldstein, L.; Gown, A.; Jones, S.J.; Griffith, O.L. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann. Surg. Oncol. 2008, 15, 2811-2826.
105. Krause, K.; Jessnitzer, B.; Fuhrer, D. Proteomics in thyroid tumor research. J. Clin. Endocrinol. Metab. 2009, 94, 2717-2724.
106. Manne, U.; Srivastava, R.G.; Srivastava, S. Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discov. Today 2005, 10, 965-976.
107. Wang, J.X.; Yu, J.K.; Wang, L.; Liu, Q.L.; Zhang, J.; Zheng, S. Application of serum protein fingerprint in diagnosis of papillary thyroid carcinoma. Proteomics 2006, 6, 5344-5349.
108. Wulfkuhle, J.D.; Liotta, L.A.; Petricoin, E.F. Proteomic applications for the early detection of cancer. Nat. Rev. Cancer 2003, 3, 267-275.
109. Gillette, M.A.; Mani, D.R.; Carr, S.A. Place of pattern in proteomic biomarker discovery. J. Proteome Res. 2005, 4, 1143-1154.
110. Shen, Y.; Jacobs, J.M.; Camp, D.G.; Fang, R.; Moore, R.J.; Smith, R.D.; Xiao, W.; Davis, R.W.; Tompkins, R.G. Ultra-High-Efficiency Strong Cation Exchange LC/RPLC/MS/MS for High Dynamic Range Characterization of the Human Plasma Proteome. Anal. Chem. 2004, 76, 1134-1144.
111. Srisomsap, C.; Subhasitanont, P.; Otto, A.; Mueller, E.C.; Punyarit, P.; Wittmann-Liebold, B.; Svasti, J. Detection of cathepsin B up-regulation in neoplastic thyroid tissues by proteomic analysis. Proteomics 2002, 2, 706-712.
112. Brown, L.M.; Helmke, S.M.; Hunsucker, S.W.; Netea-Maier, R.T.; Chiang, S.A.; Heinz, D.E.; Shroyer, K.R.; Duncan, M.W.; Haugen, B.R. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol. Carcinog. 2006, 45, 613-626.
113. Netea-Maier, R.T.; Hunsucker, S.W.; Hoevenaars, B.M.; Helmke, S.M.; Slootweg, P.J.; Hermus, A.R.; Haugen, B.R.; Duncan, M.W. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res. 2008, 68, 1572-1580.
114. Nair, S.; Wearsch, P.A.; Mitchell, D.A.; Wassenberg, J.J.; Gilboa, E.; Nicchitta, C.V. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J. Immunol. 1999, 162, 6426-6432.
115. Obeid, M.; Tesniere, A.; Ghiringhelli, F.; Fimia, G.M.; Apetoh, L.; Perfettini, J.L.; Castedo, M.; Mignot, G.; Panaretakis, T.; Casares, N.; et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13, 54-61.
116. Giusti, L.; Iacconi, P.; Ciregia, F.; Giannaccini, G.; Basolo, F.; Donatini, G.; Miccoli, P.; Lucacchini, A. Proteomic analysis of human thyroid fine needle aspiration fluid. J. Endocrinol. Invest. 2007, 30, 865-869.
117. Giusti, L.; Iacconi, P.; Ciregia, F.; Giannaccini, G.; Donatini, G.L.; Basolo, F.; Miccoli, P.; Pinchera, A.; Lucacchini, A. Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. J. Proteome Res. 2008, 7, 4079-4088.
118. Torres-Cabala, C.; Bibbo, M.; Panizo-Santos, A.; Barazi, H.; Krutzsch, H.; Roberts, D.D.; Merino, M.J. Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol. 2006, 50, 518-528.
119. Krause, K.; Karger, S.; Schierhorn, A.; Poncin, S.; Many, M.C.; Fuhrer, D. Proteomic profiling of cold thyroid nodules. Endocrinology 2007, 148, 1754-1763.
120. Moretz, W.H.; Gourin, C.G.; Terris, D.J.; Xia, Z.S.; Liu, Z.; Weinberger, P.M.; Chin, E.; Adam, B.L. Detection of papillary thyroid carcinoma with serum protein profile analysis. Arch. Otolaryngol. Head Neck Surg. 2008, 134, 198-202.
121. Fan, Y.; Shi, L.; Liu, Q.; Dong, R.; Zhang, Q.; Yang, S.; Fan, Y.; Yang, H.; Wu, P.; Yu, J.; et al. Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol. Cancer. 2009, 8, 79.
122. Suriano, R.; Lin, Y.; Ashok, B.T.; Schaefer, S.D.; Schantz, S.P.; Geliebter, J.; Tiwari, R.K. Pilot study using SELDI-TOF-MS based proteomic profile for the identification of diagnostic biomarkers of thyroid proliferative diseases. J. Proteome Res. 2006, 5, 856-861.
123. Iannetti, A.; Pacifico, F.; Acquaviva, R.; Lavorgna, A.; Crescenzi, E.; Vascotto, C.; Tell, G.; Salzano, A.M.; Scaloni, A.; Vuttariello, E.; et al. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc. Natl. Acad. Sci. USA 2008, 105, 14058-14063.
124. Dunn, L.L.; Rahmanto, Y.S.; Richardson, D.R. Iron uptake and metabolism in the new millennium. Trends Cell Biol. 2007, 17, 93-100.
125. Semenza, G.L. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001, 107, 1-3.
126. Rius, J.; Guma, M.; Schachtrup, C.; Akassoglou, K.; Zinkernagel, A.S.; Nizet, V.; Johnson, R.S.; Haddad, G.G.; Karin, M. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008, 453, 807-811.
127. Arcinas, A.; Yen, T.Y.; Kebebew, E.; Macher, B.A. Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J. Proteome Res. 2009, 8, 3958-3968.
128. Gorla, L.; Mondellini, P.; Cuccuru, G.; Miccichè, F.; Cassinelli, G.; Cremona, M.; Pierotti, M.A.; Lanzi, C.; Bongarzone, I. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements. Mol. Carcinog. 2009, 48, 220-231.
129. Dietel, M.; Sers, C. Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch. 2006, 448, 744-755.